1073485-22-9

Basic information

• Product Name: 4-chloro-6-(2-ethoxy-phenyl)-pyrimidine
• Synonyms: 4-chloro-6-(2-ethoxy-phenyl)-pyrimidine
• CAS NO: 1073485-22-9
• Molecular Weight: 234.685
• Mol File: 1073485-22-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-chloro-6-(2-ethoxy-phenyl)-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6-(2-ethoxy-phenyl)-pyrimidine(1073485-22-9)
• EPA Substance Registry System: 4-chloro-6-(2-ethoxy-phenyl)-pyrimidine(1073485-22-9)

Safety Data

• Hazardous Substances Data: 1073485-22-9(Hazardous Substances Data)

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 213211-69-9 (2-ethoxyphenyl)boronic acid 

Downstream Products

• 1073589-70-4 {4-[6-(2-ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-methanesulfonamide 
• 1073484-21-5 (3-[6-(2-ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl)-methanesulfonamide 
• 1606169-30-5 ethyl (3-{[6-(2-ethoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate 

Relevant articles and documents

Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors

Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

INHIBITORS OF PROTEIN KINASES

The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

Inhibitors of protein kinases

The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.